A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a pharmaceutical company with a market capitalization of $22.74 million, has entered into a material definitive agreement and closed a private investment in ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

SAN FRANCISCO--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage ... In addition, we announced our second lead pipeline program for the treatment of acromegaly with clinical development ...

Company to present pipeline update at 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT -- BOSTON, January 09, 2025--(BUSINESS WIRE)--Nimbus Therapeutics ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today highlighted its recent pipeline achievements and ...

pipeline, and anticipated milestones for 2025 and beyond at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT. Nimbus Therapeutics is a clinical-stage ...

Company to present pipeline update at 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT -- Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a ...

Exclusive agreement to acquire Nudge Therapeutics includes their series of cGAS inhibitors. Nudge has developed novel potent small molecule cGAS inhibitors that prevents the overproduction of Type ...